Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0IXKOE
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
RFB4-SMPT-dgA
|
|||||
| Synonyms |
Anti-CD22 monoclonal antibody RFB4-ricin chain A conjugate; IgG-RFB4-SMPT-dgA; Monoclonal antibody RFB4-ricin chain A conjugate; NSC 639179; NSC639179; RFB4-SMPT-dgA
Click to Show/Hide
|
|||||
| Organization |
National Cancer Institute; The University of Texas Southwestern Medical Center
|
|||||
| Drug Status |
Phase 1 (Terminated)
|
|||||
| Indication |
In total 1 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
Undisclosed
|
|||||
| Antibody Name |
RFB4
|
Antibody Info | ||||
| Antigen Name |
B-cell receptor CD22 (CD22)
|
Antigen Info | ||||
| Payload Name |
Deglycosylated ricin A-chain (dgA)
|
Payload Info | ||||
| Linker Name |
Succynimidyloxycarbonyl-alpha-methyl-alpha-(2-pyridyl-dithio) toluene (SMPT)
|
Linker Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
| Puchem SID | ||||||
